Free Trial

Daiichi Sankyo (OTCMKTS:DSNKY) Trading Down 0.8% - What's Next?

Daiichi Sankyo logo with Medical background

Key Points

  • Daiichi Sankyo's stock experienced a decline of 0.8% recently, trading at $22.27 after a previous close of $22.45, with a significant increase in trading volume of 338% compared to its average.
  • The company received a "strong-buy" rating from Nomura Securities, contributing to an overall average rating of "Strong Buy" based on analyst evaluations.
  • Daiichi Sankyo currently holds a market capitalization of $42.19 billion and has a low debt-to-equity ratio of 0.06, indicating strong financial health.
  • MarketBeat previews the top five stocks to own by October 1st.

Daiichi Sankyo Co., Ltd. - Sponsored ADR (OTCMKTS:DSNKY - Get Free Report) was down 0.8% on Monday . The stock traded as low as $22.03 and last traded at $22.27. Approximately 760,310 shares were traded during mid-day trading, an increase of 338% from the average daily volume of 173,583 shares. The stock had previously closed at $22.45.

Analyst Upgrades and Downgrades

Separately, Nomura Securities upgraded Daiichi Sankyo to a "strong-buy" rating in a research report on Friday, June 6th. One research analyst has rated the stock with a Strong Buy rating, Based on data from MarketBeat.com, the stock currently has an average rating of "Strong Buy".

Check Out Our Latest Report on Daiichi Sankyo

Daiichi Sankyo Price Performance

The company has a debt-to-equity ratio of 0.06, a current ratio of 2.31 and a quick ratio of 1.60. The stock has a 50 day simple moving average of $24.39 and a two-hundred day simple moving average of $24.19. The company has a market cap of $42.19 billion and a price-to-earnings ratio of 21.01.

About Daiichi Sankyo

(Get Free Report)

Daiichi Sankyo Company, Limited manufactures, markets, and sells pharmaceutical products worldwide. The company offers Enhertu, a HER2 directed antibody drug conjugate; Turalio, a CSF-1R inhibitor; Vanflyta, a FLT3 inhibitor for the treatment of adult patients with relapsed/refractory FLT3-ITD acute myeloid leukemia; ferric carboxymaltose injection for treating anaemia; and Injectafer for the treatment for iron deficiency anaemia.

See Also

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in Daiichi Sankyo Right Now?

Before you consider Daiichi Sankyo, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Daiichi Sankyo wasn't on the list.

While Daiichi Sankyo currently has a Strong Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

Ten Starter Stocks For Beginners to Buy Now Cover

Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.

Get This Free Report
Like this article? Share it with a colleague.